Clinical Trial Update: PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients [Phase 3]

View source ↗

Summary

Phase 3 PROVIDENCE-1 trial of rifalazil in Chlamydia pneumoniae seropositive patients with peripheral vascular disease or intermittent claudication has an unkno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Vascular Disease

Drugs mentioned

• Rifalazil (rifalazil)

Snippet

Sponsor: ActivBiotics | Conditions: Peripheral Vascular Diseases, Intermittent Claudication | Phase 3 | Status: UNKNOWN